Orgenesis Stock Number Of Employees
Fundamental analysis of Orgenesis allows traders to better anticipate movements in Orgenesis' stock price by examining its financial health and performance throughout various phases of its business cycle.
Orgenesis |
Orgenesis Company Number Of Employees Analysis
Orgenesis' Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Current Orgenesis Number Of Employees | 146 |
Most of Orgenesis' fundamental indicators, such as Number Of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orgenesis is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
CompetitionBased on the recorded statements, Orgenesis is currently employing 146 people. This is 98.67% lower than that of the Biotechnology sector and 72.73% lower than that of the Health Care industry. The number of employees for all United States stocks is 99.23% higher than that of the company.
Orgenesis Number Of Employees Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orgenesis' direct or indirect competition against its Number Of Employees to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Orgenesis could also be used in its relative valuation, which is a method of valuing Orgenesis by comparing valuation metrics of similar companies.Orgenesis is currently under evaluation in number of employees category among its peers.
Orgenesis Fundamentals
Return On Equity | -7.27 | ||||
Return On Asset | -0.3 | ||||
Operating Margin | (16.54) % | ||||
Current Valuation | 23.01 M | ||||
Shares Outstanding | 4.77 M | ||||
Shares Owned By Insiders | 21.16 % | ||||
Shares Owned By Institutions | 4.54 % | ||||
Number Of Shares Shorted | 56.25 K | ||||
Price To Earning | 7.52 X | ||||
Price To Book | 1.26 X | ||||
Price To Sales | 15.21 X | ||||
Revenue | 530 K | ||||
Gross Profit | 36.02 M | ||||
EBITDA | (54.07 M) | ||||
Net Income | (64.92 M) | ||||
Cash And Equivalents | 2.3 M | ||||
Cash Per Share | 0.09 X | ||||
Total Debt | 22.62 M | ||||
Debt To Equity | 0.64 % | ||||
Current Ratio | 1.57 X | ||||
Book Value Per Share | (3.30) X | ||||
Cash Flow From Operations | (14.84 M) | ||||
Short Ratio | 2.39 X | ||||
Earnings Per Share | (8.00) X | ||||
Target Price | 6.0 | ||||
Number Of Employees | 146 | ||||
Beta | 1.21 | ||||
Market Capitalization | 10.07 M | ||||
Total Asset | 14.55 M | ||||
Retained Earnings | (176.62 M) | ||||
Working Capital | (12.33 M) | ||||
Current Asset | 5.29 M | ||||
Current Liabilities | 14.92 M | ||||
Net Asset | 14.55 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Orgenesis Pink Sheet
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |